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Background: Children with cystic ﬁbrosis (CF) are often Pseudomonas aeruginosa (PsA) free and exhibit normal spirometry between the ages of 5
and 7. It is reported that computed tomography (CT) is more sensitive than FEV1 as an instrument in the identiﬁcation of pulmonary disease. It is
not known whether CF-CT scores in childhood may be used to highlight children at risk of developing severe disease.
Aims: 1— To assess the number of respiratory exacerbations (RTEs) during a follow-up period of 6 years and their correlation with the CF-CT
scores in young CF children. 2— To assess whether PsA-negative CF children with high chest CF-CT scores are more likely to develop chronic
PsA lung infection.
Methods: 68 chest CT performed in patients without chronic PsA infection were scored. All patients (median age 7.8 years) had at least 4 clinical,
functional and microbiologic assessments/year in the subsequent 6 years. RTE was deﬁned as hospitalization and IV antibiotic treatment for
respiratory symptoms.
Results: 86.8% patients had b3 RTEs in the 6 year follow-up period. The number of RTEs in the 6 years subsequent to the CT scan was correlated
to the bronchiectasis CT score (BCTS) (r = 0.612; p b 0.001) and to FEV1 at baseline (r = −0.495, p b 0.001). A BCTS≥17.5 identiﬁed patients
with N3 RTEs during follow-up (sensitivity: 100%, speciﬁcity: 85%), while FEV1 did not. Only BCTS was signiﬁcant in a logistic multivariate
model (RR 1.15). BCTS was signiﬁcantly lower and FEV1 higher in patients who did not develop chronic PsA infection by the end of the study.
Conclusion: In CF children free from chronic PsA, both CT scores and FEV1 values demonstrate signiﬁcant correlation with disease severity in the
subsequent 6 years but CT score has higher predictive value in the identiﬁcation of patients at risk.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Computed tomography; Respiratory exacerbations; Pseudomonas aeruginosa1. Introduction
Cystic fibrosis (CF) lung disease is progressive and
characterized by the development of bronchiectasis andresponding author at: Verona Regional Cystic Fibrosis Centre, Piazzale
1, 37126 Verona, Italy. Tel.: +39 045 812 3025; fax: +39 812 3021.
ail address: carlafbortoluzzi@gmail.com (C.-F. Bortoluzzi).
x.doi.org/10.1016/j.jcf.2014.03.006
993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aregional air trapping, chronic lower-airway bacterial infection,
respiratory tract exacerbations (RTEs) and progressive decrease
in lung function. Traditionally, spirometry (i.e. forced expira-
tory volume in 1 s or FEV1) has been used to monitor disease
progression.
Recent data show that chest CT can help us identify
structural abnormalities in children who are too young to
perform routine spirometry that gives reliable values [1–3].ll rights reserved.
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other disadvantages, for example its high cost, chest CT has
become the gold standard for the diagnosis of bronchiectasis in
CF and non-CF individuals [4,5]. The role of chest CT in
monitoring the progression of CF lung disease has been
extensively studied in the last few years, thanks to standard-
ization of quantitative CF scoring systems [6]. A comparison
between the CF-CT score, which is an upgraded version of the
Brody CT scoring system, and other surrogate clinical
endpoints in CF [7–9] shows that the high sensitivity of the
bronchiectasis subscore is of more utility in diagnosis and
tracking of early lung disease compared to FEV1 [2,10].
Longitudinal studies are needed to establish whether
early-age CF-CT scores identify those patients who will then
develop severe lung disease during adolescence or young
adulthood.
Disease progression in CF is related to RTEs and chronic
lung Pseudomonas aeruginosa (PsA) infection [11]. RTE is an
accepted outcome in CF [12,13], although there is no consensus
on its definition [14]. Up to this date however only two studies
[7,15] have examined the correlation between chest CT scores
and later RTEs in these patients; the follow-up period in both
was 2 years. In addition, it is not clear whether the presence of
bronchiectasis precedes PsA infection and thus whether it is an
early determinant of lung disease progression.
The first aim of our study was to examine the association
between chest CT scores and RTE over a longer period to
establish whether they can identify those patients who are at
risk of deteriorating. To our knowledge, there are no studies
which describe the correlation between chest CT scores and
RTEs over an extended follow-up in children with CF who are
PsA free.
The second aim of our study was to investigate, in the cohort
of young PsA-negative CF patients, whether CT scores and FEV1
could be used to identify those patients who are more likely to
develop chronic PsA infection before adolescence. We investi-
gated the abovementioned associations in a cohort of patients
who all had 6 years of clinical, functional and microbiological
follow-up after the first chest CT.
2. Methods
2.1. Study population
This retrospective analysis includes all eligible patients with
a confirmed diagnosis of CF who had a chest CT scan during
the period from January 2004 to April 2007 and who were
subsequently followed in the Verona CF Regional Centre
(Italy). Since 2004, starting from when they can reliably do
pulmonary function tests, all of our patients have a routine chest
CT scan every 2 to 3 years. We included only those CT scans
performed as part of an annual check up when patients were
clinically stable.
Eligible children 1) were aged ≥4 and ≤11 years, 2) had
been diagnosed with CF (sweat chloride ≥60 mmol/l and/or
two known CF mutations), and 3) were monitored for 6 years in
our center, with at least quarterly clinical, spirometric andmicrobiological assessments every year throughout the period.
We excluded: 1) patients for whom we had incomplete
follow-up data and 2) patients who had a lung transplant before
the end of the follow-up. The hospital review board approved the
study protocol, and parents' written informed consent was
obtained.
2.2. Follow-up assessments
Patients were seen every three months and assessed
according to the European CF Society Standards of Care [16].
Clinical data were extracted from electronic patient records.
2.3. Chest CT scans
A single 4-detector row CT scanner (Somatom Plus 4,
Siemens, Berlin, Germany) was used. The CT scans were
obtained in the supine position using the following scan
parameters: 80–120 kVp, 15–24 mAs, pitch of 1, with auto-
matic tube current modulation. The lung parenchyma was
evaluated using the following HRCT reconstruction parameters:
1 mm slice thickness at 3 to 10 mm intervals from apex to base
during voluntary end inspiration breath-holds in cooperative
patients. The calculated Dose Length Product or DLP range
(DLP = volume CTDI ∗ scan length) for the CT scans was 22–
113 mGy ∗ cm (estimated mSv range: 0.34–1.74).
2.4. CT scoring
All CTs were scored using a CF-CT scoring system (Brody
II), proposed by Brody and colleagues [6]. Bronchiectasis,
mucus plugging, airway wall thickening and parenchyma
scores were calculated for each patient; air trapping was not
evaluated. The maximum total CT score (243) is the sum of
maximum values for each parameter (bronchiectasis, mucus
plugging, airway wall thickening, opacities, air trapping) for
every single lung lobe, considering the lingula as a separate
lobe. Excluding air trapping, the maximum theoretical value is
216. For statistical analysis, only partial subscores were
considered and expressed as a percentage of the maximum
possible score (0–100).
All 73 scans were anonymized, randomized and scored
using a modified Brody score [6] by two suitably qualified,
independent observers (S.V. and M.L.). Mean CT scores were
used for analysis.
2.5. Spirometry, respiratory cultures and exacerbations
All spirometry measurements were obtained using a single
water bell spirometer (Biomedin, Padova, Italy). Forced
expiratory volume in 1 s (FEV1), forced vital capacity (FVC)
and forced expiratory flow between 25 and 75% of FVC (FEF
25–75) were expressed as percentages of predicted values and
as Z scores. Reference equations for children by Zapletal and
Samanek [17] were used.
Deep throat or sputum cultures were obtained at least every
three months. The prevalence of PsA infection was assessed
Table 1
Cohort characteristics at baseline (chest CT) and after 6 years.
Descriptives Baseline (mean ± SD)
(range)
6 years later
N included patients 68 68
Age, years 7.76 ± 1.57 (4.6–10.8) –
Height, cm 127.9 ± 13.0 (103.9–164.1) –
Weight, kg 29.5 ± 7.3 (15.2–50.9) –
BMI, kg/m2 16.8 ± 1.87 (13.1–22.5) –
BMI percentile 44.3 ± 28.1 –
FEV1% 85.0 ± 16.0 (44.8–117) 85.7 ± 17.3
(46.1–118)
FVC % predicted 96.1 ± 12.9 (65.5–120.5) 95.6 ± 13.3
(67.3–127)
FEF 25–75% predicted 66.9 ± 27.9 (14.8–123.5) 65.4 ± 28.9
(17.5–138)
CF-CT bronchiectasis score 12.5 ± 10.1 (0–41.3) –
CF-CT mucus plugging score 4.9 ± 7.8 (0–31.9) –
CF-CT airway wall
thickening score
11.3 ± 11.0 (0–40.7) –
CF-CT parenchyma score 4.9 ± 4.3 (0–13) –
Chronic MSSA infection 30 (44.1%) 25 (36.8%)
Chronic MRSA infection 0 6 (8.8%)
N pancreatic
insufficiency
57 –
N Phe508del mutation
homozygosis
19 –
Allergic bronchopulmonary
aspergillosis
1 1
CF related diabetes 0 1
Abbreviations: BMI: body mass index; CT: computed tomography; FEV1:
forced expiratory volume in 1 s; FEF 25–75: forced expiratory flow between 25
and 75% of FVC; FVC: forced vital capacity; MSSA: methicillin-sensible
Staphylococcus aureus; MRSA: methicillin-resistant S. aureus.
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year of the study period. Infection was defined according to the
Leeds criteria [18]: 1) never; PsA never cultured from sputum
or pharyngeal samples; 2) free; no growth of PsA found in the
previous 12 months, having previously been PsA culture
positive; 3) intermittent; when 50% or fewer of the samples
were positive for PsA; and 4) chronic; when sputum or
pharyngeal samples were positive for PsA in more than 50% of
the cultures in a 12 month period. The presence of Staphylo-
coccus aureus (methicillin sensible — MSSA- and methicillin
resistant — MRSA) was assessed at the time of the CT and at
the end of follow-up. A MSSA infection was defined chronic
when sputum or pharyngeal samples were positive for PsA in
more than 50% of the cultures in a 12 month period. The
presence of other bacteria was also recorded at the time of the
CT.
We recorded data about all hospitalizations for IV antibiotic
treatment for respiratory symptoms in the 6 years following the
baseline CT.
Only baseline CT scans were compared with baseline and
follow-up parameters, including subsequent RTEs.
2.6. Statistical analysis
The interobserver agreement of the CT scores was calculated
using an intraclass correlation coefficient (ICC). An ICC of
N0.8 is generally considered to indicate very strong agreement.
Descriptive statistics were calculated for each parameter
(gender, age, spirometry measurements, colonization, RTEs):
percentages were reported for discrete variables, while median,
range, mean and standard deviations were calculated for the
continuous variables.
Patient characteristics were compared using X2 or Fisher's
exact test (as appropriate) for discrete variables and the
Kruskal–Wallis test for comparison of more than two groups
for the continuous variables. The correlations between contin-
uous variables were computed. The Pearson correlation
coefficients were interpreted according to the Salkin scale: an
r value between 0.8 and 1.0 (or −0.8 and −1.0) is defined as
very strong, 0.6–0.8 as strong, 0.4–0.6 as moderate, 0.2–0.4 as
weak and 0.0–0.2 as very weak or as no relationship [19].
CT scan scores and FEV1 results were grouped into
quartiles. A receiver–operator characteristic (ROC) curve was
plotted to find the CF-CT score value that was identified, with
the highest sensitivity and specificity, those subjects who
experienced 4 or more RTEs during the follow-up. The optimal
cut-off points of parameters were selected according to the
maximum Youden's index value (sensitivity + specificity-1).
A logistic regression model was estimated to determine which
variables were associated with the number of RTEs in a 6-year
follow-up. Univariate analysis was performed for the following
variables: FEV1%, age, BMI, BMI%, and BCTS. All variables
having a p b 0.1 entered a multivariate logistic model.
A p value b 0.05 was considered statistically significant.
Version 11 of SPSS (SPSS Inc., Chicago, Illinois) and SAS
(SAS Institute, Cary, NC, USA; Version 9.2) softwares were
used for statistical analysis.3. Results
3.1. Characteristics of the subjects
83 subjects had chest CT during the study period. 10 patients
were eventually excluded as they did not meet the inclusion
criteria (2 were lost during follow-up and follow-up data was
incomplete for 8), therefore 73 subjects were eligible for the
study. We performed the analysis excluding those patients who
had already chronic PsA infection at the time of CT scan (n =
5) because this condition influences the disease severity and the
prevalence of RTEs. Therefore we eventually included 68
patients in the study. Median age at CT was 7.8 years in the
range 4.6–10.8, 36 (52.9%) were female. Subject characteris-
tics are shown in Table 1.
All CT scans scored were of good quality and considered by
an experienced radiologist to be adequate for evaluation.3.2. RTEs
In the 6 years following the CT, 47.1% of the patients had
no RTEs, 39.7% experienced from 1 to 3 and 13.2% had more
than 3. The median number of RTEs in the follow-up period
was 1 (range 0–15, interquartile range 0–2).
Table 2
Characteristics of patients according to the number of RTEs.
RTEs in 6 years 0 (N = 32) 1–3 (N = 27) N3 (N = 9)
Age (years, SD) 7.65 (1.38) 7.63 (1.80) 8.51 (1.45)
BMI percentile, mean (SD) 49.10 (28.27) 39.58 (27.16) 41.63 (30.30)
FEV1% at CT, mean (SD) 92.81 (12.32) 80.40 (15.69) 70.97 (14.28)
FEF 25–75% at CT, mean (SD) 79.29 (22.42) 57.88 (22.99) 40.98 (18.93)
BCTS (mean, SD) 7.52 (5.66) 14.10 (10.61) 25.68 (8.09)
Abbreviations: see Table 1.
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Interobserver agreement was strong for bronchiectasis CT
score (BCTS) (ICC N 0.95) but, consistently with previously
reported data [7], weak for mucus plugging (0.40), and airway
wall thickening (0.00). ICC for parenchyma scores was 0.92.
Only the BCTS was considered for analysis.
A high correlation coefficient was found between the BCTS
and the number of RTEs in the following 6 years (r = 0.612,
p b 0.001); the correlation coefficients between FEV1% or
FEF 25–75% at baseline and RTEs were lower but still
significant (r = −0.495 and −0.493 respectively, p b 0.001).
The correlations between BCTS and initial FEV1% or FEF 25–
75% and between BCTS and FEV1% or FEF 25–75% at the
end of follow-up were low (r = −0.37 and −0.43 respectively,
p b 0.05 for FEV1%; and r = −0.32 and −0.36 respectively,
p b 0.05 for FEF 25–75%).
Patients with the highest BCTS and lowest FEV1% values
had the highest rates of RTEs. Patients with N3 RTEs had
significantly higher BCTS compared to those with 1 to 3 or no
RTEs over the follow-up period (mean 25.7 ± 8.1, 14.1 ± 10.6
and 7.5 ± 5.7 respectively, p b 0.001). Descriptive data for
these groups are presented in Table 2.
Fig. 1 shows the ROC curves for BCTS and FEV1 and their
best cut-offs. A BCTS ≥17.5 identified patients with N3 RTEsFig. 1. ROC curves for bronchiectasis CT score (A) and FEV1 (B) identifying patient
left corner, the greater the discriminatory ability of the test. The straight, diagonal lin
bronchiectasis CT score is 0.914 (cut off 17.5%: sensitivity 100%, specificity 85%)with a sensitivity of 100% and a specificity of 85% (Youden's
index = 0.85). The best cut off for FEV1% (88.7) with a 100%
sensitivity had a very low specificity (50.8%) (Youden's
index = 0.49).
Among the variables analyzed (age, BMI, BMI%, FEV1,
BCTS), FEV1 and BCTS resulted significant in univariate
analysis; this result was confirmed in the multivariate model
only for BCTS. For every one unit increase in CT score, the
odds ratio of having more than 3 RTEs increases by 15% (OR
1.15; 95% C.I.: 1.06–1.25, p = 0.0009).
3.4. P. aeruginosa lung infection and CT score
In this cohort, 18 patients had no PsA cultured in their
lifetime including up to the end of follow-up (group A). 38
patients, who had PsA cultured at least once in their lifetime,
were PsA free or intermittent in the year before performing chest
CT and were still PsA free or intermittent at the end of follow-up
(group B), while 12 free or intermittent in the year before chest
CT became PsA chronic in the 6-year follow-up (group C). We
found that BCTS at baseline was significantly different in the
three groups, being higher in group C than group B and higher in
group B than in group A (mean 20.1 ± 9.3, 12.9 ± 10.8 and
6.6 ± 6.6 respectively; p = 0.0003). FEV1% and FEF 25–75%
at the time of CT scans were significantly different in the three
groups although higher in group A and group B and lower in
group C (Table 3 and Fig. 2).
3.5. Other microorganisms
We also analyzed the presence of co-infection with MSSA,
MRSA and other microorganisms. At the time of the CT, none
of the 68 patients had MRSA, while 3 (16.7%) patients in group
A, 19 (50%) in group B and 8 (66.7%) [8] in group C had
chronic MSSA. At the end of follow-up, in group A 7 (38.9%)s who had N3 RTEs in 6 years. The closer the apex of the curve toward the upper
e represents Area Under Curve (AUC) = 0.5 (no discriminative value). AUC for
. AUC for FEV1 is 0.785 (cut off 88.7%: sensitivity 100%, specificity 50.8%).
Table 3
Kruskal Wallis test comparing group A (never PsA), B (PsA free or intermittent within the study) and C (free or intermittent PsA at baseline with chronic infection at
end of follow-up).
PsA infection
Group A Group B Group C p
Bronchiectasis CT score%
Median (range) 4.9 (0.0–26.9) 11.4 (0–41.3) 21.2 (5.6–33.9) 0.0003
Mean (SD) 6.6 (6.6) 13.0 (10.2) 20.1 (9.3)
N obs. 18 38 12
FEV1% at CT
Median (range) 88.9 (71–114) 90 (44.8–117) 73.0 (52.8–82.8) 0.0019
Mean (SD) 90.7 (11.8) 86.5 (17.1) 71.7 (9.8)
N obs. 18 38 12
FEF 25–75% at CT
Median (range) 74.3 (30.7–123.5) 69.8 (26–118) 42.3 (14.8–79.3) 0.0084
Mean (SD) 72.4 (27.8) 69.8 (24.4) 43.6 (17.2)
N obs. a 16 33 11
Age at CT, years
Median (range) 6.7 (4.6–9.9) 7.9 (5.2–10.8) 8.5 (5.1–10.8) 0.1325
Mean (SD) 7.2 (1.7) 7.9 (1.4) 8.3 (1.7)
N obs. 1 8 3 8 12
Height, cm
Median (range) 121.8 (104.8–164.1) 128.2 (103.9–145.9) 132.1 (109.9–148) 0.4
Mean (SD) 125.7 (15.2) 127.9 (12.4) 131.3 (11.6)
N obs. 18 38 12
Weight, kg
Median (range) 27.5 (15.2–48.3) 29.5 (16.6–42.9) 29.6 (20.1–50.9) 0.7
Mean (SD) 28.3 (8.5) 29.5 (6.5) 31.4 (8.2)
N obs. 18 38 12
BMI, kg/m2
Median (range) 16.4 (13.1–20.3) 16.6 (13.9–20.7) 15.8 (14.8–22.5) 0.5
Mean (SD) 16.4 (1.9) 16.8 (1.7) 17.2 (2.3)
N obs. 18 38 12
BMI%
Median (range) 38.9 (1.2–96.9) 45.6 (3.6–92.7) 26.9 (10.2–94.7) 0.97
Mean (SD) 42.8 (28.9) 45.5 (27.9) 43.1 (29.7)
N obs. 18 38 12
Abbreviations: See Table 1.
a In 8 patients b7.5 years old at the time of CT, FEF 25–75% was not reported in the database because they were not fully cooperative with the test.
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(39.5%) had MSSA and 2 (5.3%) MRSA; and in group C,
3 (25.0%) had MSSA and 2 (16.7%) had MRSA. The
differences between the groups were significant at the time of
the CT (p =0.01) but not at the end of the follow-up (p = 0.7).
There were no significant differences in the overall number
of patients colonized by other microorganisms between the 3
groups (Table 4).
4. Discussion
We analyzed a cohort of CF patients without PsA chronic
infection, aged between 4 and 11 years old who had a routine
baseline chest CT scan and were then followed for the
subsequent 6 years. Our data showed that: a) a chest CT,
performed in a stable clinical condition at this age, highlights
patients at high risk of RTEs, while FEV1 is less predictive;
BMI and age do not show significant value; b) PsA-free
children with higher CT scores and lower FEV1 and FEF 25–
75 values seem to be more susceptible to developing chronic
PsA airway infection; c) patients who have never been infectedwith PsA have the lowest BCTS; and d) MSSA and MRSA
infections do not show a significantly higher prevalence in
the group of patients who had chronic PsA at the end of the
follow-up. The prevalence of other bacteria does not differ in
patients who never had PsA and in those who became
chronically infected.
Bronchiectasis and chronic PsA infection are the two most
important determinants in CF lung disease progression and are
associated with increased morbidity and early mortality
[11,20]. Chest CT provides a direct and sensitive means of
measuring early structural changes in the lung of patients
affected by CF [5]. Moreover it has been reported that CT scans
highlight lung disease earlier than FEV1% [2,10]. This was
better defined in a logistic model: in children free from chronic
PsA, BCTS highlights patients at higher risk while FEV1 did
not, and these results are independent from other variables such
as age, BMI and other comorbidities (CF related diabetes,
allergic bronchopulmonary aspergillosis).
In this study we considered the number of RTEs as the main
outcome since it is an accepted clinical endpoint in clinical
trials in CF [12,13] and it is strongly related to the progression
A B C
40
50
60
70
80
90
100
110
120
FE
V1
%
 a
t C
T
A B C
0
10
20
30
40
50
B
CT
S
  p=0.0003 
  p=0.0019 
1
2
Fig. 2. Boxplots: bronchiectasis CT score [1] and FEV1 [2] in group A (never
PsA), B (PsA free or intermittent within the study) and C (free or intermittent
PsA with chronic infection at end of follow-up). Each box shows mean (dot),
median (line), interquartile range (solid box), and extreme values. Bronchiec-
tasis CT score at baseline was significantly higher in group C than in group B
and higher in group B than in group A; FEV1 was significantly lower in group
C. Abbreviations: BCTS bronchiectasis CT score.
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its definition [14].
To our knowledge, there have been only three previous
studies that demonstrate correlation between the number of
RTEs and chest CT scores. Brody and colleagues [15] analyzed
a cohort of 61 patients (age range 6–11 years) included in the
Dornase alfa trial [23]: in a 2 year follow-up, patients with high
CT scores suffered a greater number of RTEs. Considering the
relationship between the changes in CT scores over two yearsTable 4
Colonization by other microorganisms at the time of CT scan in group A (never
PsA), B (PsA free or intermittent within the study) and C (free or intermittent
PsA at baseline with chronic infection at end of follow-up).
Colonization at CT Group A
(N = 18)
Group B
(N = 38)
Group C
(N = 12)
p
All 8 (44.4%) 27 (71.0%) 8 (66.6%) 0.15
H. parainfluenzae 7 (87.5%) 21 (77.7%) 3 (37.5%)
H. influenzae 2 3 1
Serratia species – 2 2
Alcaligenes xylosoxidans – 2 –
Stenotrophomonas maltophilia – 2 1
Candida – 1 1
N1 microorganism 1 4 0and incidence of RTE, BCTS showed the highest correlation
(r = 0.35). More recently, Loeve and colleagues [7] analyzed
retrospectively the clinical data of 115 Dutch patients (aged
from 5 to 20 years) in a 2-year follow-up after a baseline chest
CT. A worse BCTS was shown to predict a higher rate of
RTEs. The same correlation was confirmed in a recent study
correlating CT score and quality of life in CF [9]. Our study
expands therefore on previous observations but over a much
longer follow-up period and with a different, clinically relevant
cohort of young children without chronic PsA infection.
Previously, little correlation between chest CF-CT scores
and FEV1 [2,6,10] has been described and this was confirmed
in this study. BCTS carries the most weight in most scoring
systems since it is more closely correlated with RTEs and
FEV1% than the total score and other subscores [7,10,24]. Our
study confirms that BCTS is more significant than other CT
parameters. We could identify a BCTS threshold with good
sensitivity and specificity for patients at higher risk. Our
findings suggest that chest CT should be done early with CF
children, before they can do spirometry testing. Along with
infant lung function tests such as LCI [25], it could help to
highlight patients at risk of RTE and rapidly progressive lung
disease.
We found that the pediatric CF patients who remained PsA
free until the end of the follow-up had the lowest values of
BCTS and the highest FEV1% mean values. Patients who were
infection free or with intermittent infections with lower FEV1%
and FEF 25–75% values and higher CF–CT scores at the age of
7 were also more at risk of becoming chronically infected in
subsequent years. To our knowledge, very few studies have
investigated the association between CT scores and PsA
infection in CF lung. Robinson and colleagues [26] found
significant differences in chest CT scores in different groups of
children, according to their PsA status in the previous
19 months (PsA retrospectively ever detected vs never
detected). Farrell and colleagues [27] showed that there was a
correlation between chest CT scores and concomitant mucoid
PsA infection but failed to demonstrate any correlation between
chest CT scores and non-mucoid strains; we did not use such a
distinction. A recent Australian study [28] suggests that
bronchoalveolar lavage-directed antimicrobial therapy for
RTEs is not effective in children in the first 5 years of life in
reducing prevalence of future PsA infection or in lowering CT
scores. None these studies however investigated, specifically
and prospectively, PsA-free children to assess the risks of
future infection.
Recent data suggest that simultaneous infection by PsA and
MRSA could worsen lung disease [29]. In our cohort, none of
the patients had MRSA at CT. At the end of the follow-up,
4 patients with previous chronic MSSA had chronic MRSA,
2 acquired intermittent MRSA infection; the prevalence was
not significantly different in the 3 groups previously defined
according to PsA status. However, the number of MSSA
infected patients increases over 6 years in group A (never PsA)
while it decreases in group B (PsA free or intermittent within
the study) and in group C (free or intermittent at baseline with
chronic infection at the end of follow-up). This could signify
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severe CF structural lung disease.
The prevalence of co-infection with other bacteria at the
time of CT was not significantly different in these groups.
Our study has several limitations. First, data were collected
retrospectively and RTE was defined according to a common
shared definition (i.e. respiratory symptoms requiring IV
treatment), which could exclude minor RTEs that require
home treatment with oral antibiotics. Unlike the other studies,
we did not consider the number of RTEs prior to the beginning
of the follow-up. Furthermore air trapping score, which
represents small airways involvement and is a relevant early
marker of CF lung disease, was not computed because
expiratory scans were not available in this young cohort. We
did not include an analysis of CT scans at the end of the
follow-up because scores were not available in all patients: this
could have provided relevant information on radiologic
progression of lung disease in the different PsA groups. We
are planning to perform this analysis in future studies.
Finally, we did not analyze the differences between mucoid
and non-mucoid PsA strains and data on colonization by
microorganisms different from PsA and MSSA/MRSA at the
end of the follow-up.
Although additional research is needed to fully understand
the mechanisms at work, our findings offer evidence for the
early identification in CF children of significant bronchiectasis
through CT, even where there is no evidence of chronic PsA
infection, and for considering such children at high risk and in
need of tailored follow-up, timing and treatment options.
Moreover, our data also support the view that lung damage
precedes chronic PsA infection. Therefore, the clinical
implications of this study are that chest CT scan should be
recommended in children with CF, even when symptomless
and before they start performing spirometry. Moreover, in those
children with higher BCTS, it may be suggested to perform
sputum cultures more frequently, as this could give more
chances to treat earlier and more aggressively every PsA new
infection. Further prospective multicenter longitudinal studies
are necessary to confirm these outcomes.References
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